nodes	percent_of_prediction	percent_of_DWPC	metapath
Sibutramine—SLC6A4—chronic obstructive pulmonary disease	0.588	1	CbGaD
Sibutramine—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.048	0.282	CbGbCtD
Sibutramine—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0324	0.19	CbGbCtD
Sibutramine—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0309	0.182	CbGbCtD
Sibutramine—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0276	0.162	CbGbCtD
Sibutramine—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0162	0.095	CbGbCtD
Sibutramine—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0153	0.0897	CbGbCtD
Sibutramine—CYP3A4—Lidocaine metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000887	0.0735	CbGpPWpGaD
Sibutramine—CYP3A4—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.000785	0.065	CbGpPWpGaD
Sibutramine—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—chronic obstructive pulmonary disease	0.000642	0.0531	CbGpPWpGaD
Sibutramine—SLC6A2—Monoamine Transport—SLC6A4—chronic obstructive pulmonary disease	0.000394	0.0326	CbGpPWpGaD
Sibutramine—SLC6A4—Serotonin Transporter Activity—IL1B—chronic obstructive pulmonary disease	0.000391	0.0324	CbGpPWpGaD
Sibutramine—SLC6A3—Monoamine Transport—SLC6A4—chronic obstructive pulmonary disease	0.000349	0.0289	CbGpPWpGaD
Sibutramine—CYP3A4—Aflatoxin B1 metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000326	0.027	CbGpPWpGaD
Sibutramine—CYP3A4—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.00025	0.0207	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—SOD3—chronic obstructive pulmonary disease	0.000224	0.0186	CbGpPWpGaD
Sibutramine—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000194	0.016	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—SOD3—chronic obstructive pulmonary disease	0.000193	0.016	CbGpPWpGaD
Sibutramine—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000175	0.000762	CcSEcCtD
Sibutramine—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000174	0.000759	CcSEcCtD
Sibutramine—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000174	0.000759	CcSEcCtD
Sibutramine—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000174	0.000757	CcSEcCtD
Sibutramine—Infection—Montelukast—chronic obstructive pulmonary disease	0.000174	0.000757	CcSEcCtD
Sibutramine—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.000173	0.000756	CcSEcCtD
Sibutramine—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000173	0.000756	CcSEcCtD
Sibutramine—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000173	0.000756	CcSEcCtD
Sibutramine—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000173	0.000753	CcSEcCtD
Sibutramine—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000172	0.000749	CcSEcCtD
Sibutramine—Hyperkinesia—Prednisone—chronic obstructive pulmonary disease	0.000172	0.000748	CcSEcCtD
Sibutramine—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000171	0.000746	CcSEcCtD
Sibutramine—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000171	0.000746	CcSEcCtD
Sibutramine—SLC6A3—NRF2 pathway—SOD3—chronic obstructive pulmonary disease	0.000171	0.0142	CbGpPWpGaD
Sibutramine—Sepsis—Prednisone—chronic obstructive pulmonary disease	0.000171	0.000745	CcSEcCtD
Sibutramine—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.00017	0.00074	CcSEcCtD
Sibutramine—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.000169	0.000737	CcSEcCtD
Sibutramine—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000168	0.000735	CcSEcCtD
Sibutramine—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000168	0.000735	CcSEcCtD
Sibutramine—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000168	0.0139	CbGpPWpGaD
Sibutramine—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000167	0.00073	CcSEcCtD
Sibutramine—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000167	0.000727	CcSEcCtD
Sibutramine—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000167	0.000727	CcSEcCtD
Sibutramine—SLC6A4—Monoamine Transport—IL1B—chronic obstructive pulmonary disease	0.000166	0.0138	CbGpPWpGaD
Sibutramine—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000166	0.000723	CcSEcCtD
Sibutramine—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000166	0.000723	CcSEcCtD
Sibutramine—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000164	0.000717	CcSEcCtD
Sibutramine—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.000164	0.000716	CcSEcCtD
Sibutramine—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000164	0.000714	CcSEcCtD
Sibutramine—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000163	0.00071	CcSEcCtD
Sibutramine—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000163	0.00071	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000163	0.000709	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000163	0.000709	CcSEcCtD
Sibutramine—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000161	0.000704	CcSEcCtD
Sibutramine—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000161	0.000704	CcSEcCtD
Sibutramine—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000161	0.0007	CcSEcCtD
Sibutramine—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00016	0.000699	CcSEcCtD
Sibutramine—SLC6A4—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.00016	0.0132	CbGpPWpGaD
Sibutramine—Vascular purpura—Prednisone—chronic obstructive pulmonary disease	0.00016	0.000696	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000159	0.000694	CcSEcCtD
Sibutramine—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000159	0.000694	CcSEcCtD
Sibutramine—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000159	0.000694	CcSEcCtD
Sibutramine—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000159	0.000692	CcSEcCtD
Sibutramine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000159	0.000692	CcSEcCtD
Sibutramine—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000158	0.000689	CcSEcCtD
Sibutramine—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	0.000157	0.000687	CcSEcCtD
Sibutramine—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000157	0.000686	CcSEcCtD
Sibutramine—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000157	0.000685	CcSEcCtD
Sibutramine—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000157	0.000685	CcSEcCtD
Sibutramine—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000157	0.000684	CcSEcCtD
Sibutramine—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000156	0.000682	CcSEcCtD
Sibutramine—Injury—Prednisone—chronic obstructive pulmonary disease	0.000155	0.000678	CcSEcCtD
Sibutramine—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000155	0.000677	CcSEcCtD
Sibutramine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000155	0.000676	CcSEcCtD
Sibutramine—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000155	0.000674	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000154	0.000672	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000154	0.000672	CcSEcCtD
Sibutramine—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000154	0.000671	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000153	0.000669	CcSEcCtD
Sibutramine—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000153	0.0127	CbGpPWpGaD
Sibutramine—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000153	0.000665	CcSEcCtD
Sibutramine—Pain—Formoterol—chronic obstructive pulmonary disease	0.000153	0.000665	CcSEcCtD
Sibutramine—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000153	0.000665	CcSEcCtD
Sibutramine—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000153	0.000665	CcSEcCtD
Sibutramine—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000152	0.000664	CcSEcCtD
Sibutramine—Amnesia—Prednisone—chronic obstructive pulmonary disease	0.000152	0.000663	CcSEcCtD
Sibutramine—Increased appetite—Prednisone—chronic obstructive pulmonary disease	0.000152	0.000663	CcSEcCtD
Sibutramine—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000151	0.00066	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000151	0.000658	CcSEcCtD
Sibutramine—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.00015	0.000655	CcSEcCtD
Sibutramine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.00015	0.000653	CcSEcCtD
Sibutramine—Pain—Montelukast—chronic obstructive pulmonary disease	0.000149	0.000652	CcSEcCtD
Sibutramine—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000149	0.000651	CcSEcCtD
Sibutramine—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000149	0.00065	CcSEcCtD
Sibutramine—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000148	0.000648	CcSEcCtD
Sibutramine—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000148	0.000648	CcSEcCtD
Sibutramine—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000148	0.000647	CcSEcCtD
Sibutramine—Purpura—Prednisone—chronic obstructive pulmonary disease	0.000148	0.000646	CcSEcCtD
Sibutramine—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000148	0.000645	CcSEcCtD
Sibutramine—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000148	0.000644	CcSEcCtD
Sibutramine—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000147	0.000642	CcSEcCtD
Sibutramine—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000147	0.000641	CcSEcCtD
Sibutramine—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000147	0.000641	CcSEcCtD
Sibutramine—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000147	0.00064	CcSEcCtD
Sibutramine—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.000147	0.0121	CbGpPWpGaD
Sibutramine—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000146	0.000639	CcSEcCtD
Sibutramine—SLC6A4—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000146	0.0121	CbGpPWpGaD
Sibutramine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000146	0.000637	CcSEcCtD
Sibutramine—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000146	0.000636	CcSEcCtD
Sibutramine—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000146	0.000636	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000145	0.000634	CcSEcCtD
Sibutramine—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000144	0.000628	CcSEcCtD
Sibutramine—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000144	0.000628	CcSEcCtD
Sibutramine—SLC6A2—Monoamine Transport—IL1B—chronic obstructive pulmonary disease	0.000143	0.0119	CbGpPWpGaD
Sibutramine—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000143	0.000623	CcSEcCtD
Sibutramine—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000143	0.000623	CcSEcCtD
Sibutramine—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.000143	0.000623	CcSEcCtD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—IL13—chronic obstructive pulmonary disease	0.000143	0.0118	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000142	0.0118	CbGpPWpGaD
Sibutramine—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000142	0.000618	CcSEcCtD
Sibutramine—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000142	0.000618	CcSEcCtD
Sibutramine—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000141	0.000615	CcSEcCtD
Sibutramine—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000141	0.000615	CcSEcCtD
Sibutramine—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000141	0.000615	CcSEcCtD
Sibutramine—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000141	0.000615	CcSEcCtD
Sibutramine—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000141	0.0116	CbGpPWpGaD
Sibutramine—Affect lability—Prednisone—chronic obstructive pulmonary disease	0.000141	0.000613	CcSEcCtD
Sibutramine—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000141	0.000613	CcSEcCtD
Sibutramine—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	0.000139	0.000608	CcSEcCtD
Sibutramine—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000139	0.000608	CcSEcCtD
Sibutramine—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000139	0.000607	CcSEcCtD
Sibutramine—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000139	0.000607	CcSEcCtD
Sibutramine—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000139	0.000605	CcSEcCtD
Sibutramine—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000139	0.000605	CcSEcCtD
Sibutramine—SLC6A4—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000139	0.0115	CbGpPWpGaD
Sibutramine—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000138	0.000604	CcSEcCtD
Sibutramine—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000138	0.000604	CcSEcCtD
Sibutramine—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000138	0.000602	CcSEcCtD
Sibutramine—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000138	0.000602	CcSEcCtD
Sibutramine—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.000138	0.000601	CcSEcCtD
Sibutramine—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000138	0.000601	CcSEcCtD
Sibutramine—SLC6A2—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.000137	0.0114	CbGpPWpGaD
Sibutramine—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000137	0.000596	CcSEcCtD
Sibutramine—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000136	0.000593	CcSEcCtD
Sibutramine—Cardiac arrest—Prednisone—chronic obstructive pulmonary disease	0.000136	0.000592	CcSEcCtD
Sibutramine—Mood swings—Prednisone—chronic obstructive pulmonary disease	0.000135	0.00059	CcSEcCtD
Sibutramine—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000135	0.0112	CbGpPWpGaD
Sibutramine—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000134	0.000584	CcSEcCtD
Sibutramine—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000133	0.000581	CcSEcCtD
Sibutramine—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000133	0.000581	CcSEcCtD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—CHRNA5—chronic obstructive pulmonary disease	0.000133	0.011	CbGpPWpGaD
Sibutramine—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000131	0.000573	CcSEcCtD
Sibutramine—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000131	0.000573	CcSEcCtD
Sibutramine—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000131	0.000573	CcSEcCtD
Sibutramine—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000131	0.000572	CcSEcCtD
Sibutramine—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000131	0.000571	CcSEcCtD
Sibutramine—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.00013	0.000567	CcSEcCtD
Sibutramine—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000129	0.000561	CcSEcCtD
Sibutramine—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000128	0.000558	CcSEcCtD
Sibutramine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000128	0.000558	CcSEcCtD
Sibutramine—SLC6A3—Monoamine Transport—IL1B—chronic obstructive pulmonary disease	0.000127	0.0105	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000127	0.0105	CbGpPWpGaD
Sibutramine—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000126	0.00055	CcSEcCtD
Sibutramine—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000126	0.00055	CcSEcCtD
Sibutramine—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000126	0.000549	CcSEcCtD
Sibutramine—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000126	0.000549	CcSEcCtD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000126	0.0104	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000126	0.0104	CbGpPWpGaD
Sibutramine—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000125	0.000547	CcSEcCtD
Sibutramine—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000124	0.000542	CcSEcCtD
Sibutramine—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000124	0.000541	CcSEcCtD
Sibutramine—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000124	0.000539	CcSEcCtD
Sibutramine—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000122	0.0101	CbGpPWpGaD
Sibutramine—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000122	0.000532	CcSEcCtD
Sibutramine—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000122	0.000532	CcSEcCtD
Sibutramine—SLC6A3—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.000122	0.0101	CbGpPWpGaD
Sibutramine—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000121	0.00053	CcSEcCtD
Sibutramine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000121	0.000527	CcSEcCtD
Sibutramine—SLC6A4—Monoamine Transport—TNF—chronic obstructive pulmonary disease	0.000121	0.01	CbGpPWpGaD
Sibutramine—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.00012	0.000521	CcSEcCtD
Sibutramine—SLC6A2—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000119	0.00987	CbGpPWpGaD
Sibutramine—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000119	0.00052	CcSEcCtD
Sibutramine—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000118	0.000514	CcSEcCtD
Sibutramine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000118	0.000514	CcSEcCtD
Sibutramine—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000117	0.00971	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.000117	0.00968	CbGpPWpGaD
Sibutramine—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000116	0.000504	CcSEcCtD
Sibutramine—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000115	0.000503	CcSEcCtD
Sibutramine—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000114	0.000496	CcSEcCtD
Sibutramine—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000113	0.000495	CcSEcCtD
Sibutramine—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000113	0.000495	CcSEcCtD
Sibutramine—Rash—Formoterol—chronic obstructive pulmonary disease	0.000112	0.000491	CcSEcCtD
Sibutramine—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000112	0.000491	CcSEcCtD
Sibutramine—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000112	0.00049	CcSEcCtD
Sibutramine—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000112	0.00049	CcSEcCtD
Sibutramine—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.000112	0.00049	CcSEcCtD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000112	0.00928	CbGpPWpGaD
Sibutramine—Headache—Formoterol—chronic obstructive pulmonary disease	0.000112	0.000487	CcSEcCtD
Sibutramine—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000112	0.000487	CcSEcCtD
Sibutramine—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000112	0.000487	CcSEcCtD
Sibutramine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000111	0.000486	CcSEcCtD
Sibutramine—SLC6A3—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000111	0.00922	CbGpPWpGaD
Sibutramine—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000111	0.000486	CcSEcCtD
Sibutramine—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000111	0.00921	CbGpPWpGaD
Sibutramine—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000111	0.000485	CcSEcCtD
Sibutramine—Rash—Montelukast—chronic obstructive pulmonary disease	0.00011	0.00048	CcSEcCtD
Sibutramine—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.00011	0.00048	CcSEcCtD
Sibutramine—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.00011	0.000479	CcSEcCtD
Sibutramine—Depression—Prednisone—chronic obstructive pulmonary disease	0.00011	0.000479	CcSEcCtD
Sibutramine—Headache—Montelukast—chronic obstructive pulmonary disease	0.000109	0.000477	CcSEcCtD
Sibutramine—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000473	CcSEcCtD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—CHRNA3—chronic obstructive pulmonary disease	0.000108	0.00897	CbGpPWpGaD
Sibutramine—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000108	0.000472	CcSEcCtD
Sibutramine—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000471	CcSEcCtD
Sibutramine—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000471	CcSEcCtD
Sibutramine—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000107	0.000467	CcSEcCtD
Sibutramine—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000107	0.000466	CcSEcCtD
Sibutramine—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000106	0.000464	CcSEcCtD
Sibutramine—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000106	0.000463	CcSEcCtD
Sibutramine—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000106	0.000463	CcSEcCtD
Sibutramine—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000106	0.000463	CcSEcCtD
Sibutramine—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000106	0.000462	CcSEcCtD
Sibutramine—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000106	0.000462	CcSEcCtD
Sibutramine—SLC6A3—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000106	0.00874	CbGpPWpGaD
Sibutramine—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000106	0.00046	CcSEcCtD
Sibutramine—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000104	0.000454	CcSEcCtD
Sibutramine—SLC6A2—Monoamine Transport—TNF—chronic obstructive pulmonary disease	0.000104	0.0086	CbGpPWpGaD
Sibutramine—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000104	0.000453	CcSEcCtD
Sibutramine—SLC6A3—Dopaminergic Neurogenesis—TGFB1—chronic obstructive pulmonary disease	0.000104	0.00859	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.000104	0.00857	CbGpPWpGaD
Sibutramine—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000103	0.000447	CcSEcCtD
Sibutramine—SLC6A4—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.000103	0.00849	CbGpPWpGaD
Sibutramine—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000102	0.00846	CbGpPWpGaD
Sibutramine—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000102	0.000446	CcSEcCtD
Sibutramine—SLC6A3—Neuronal System—CHRNA5—chronic obstructive pulmonary disease	0.000102	0.00843	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	0.000101	0.00837	CbGpPWpGaD
Sibutramine—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000101	0.000439	CcSEcCtD
Sibutramine—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.0001	0.000436	CcSEcCtD
Sibutramine—Discomfort—Prednisolone—chronic obstructive pulmonary disease	9.96e-05	0.000434	CcSEcCtD
Sibutramine—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	9.93e-05	0.000433	CcSEcCtD
Sibutramine—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	9.88e-05	0.000431	CcSEcCtD
Sibutramine—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	9.83e-05	0.00814	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—ADIPOQ—chronic obstructive pulmonary disease	9.66e-05	0.008	CbGpPWpGaD
Sibutramine—Oedema—Prednisolone—chronic obstructive pulmonary disease	9.66e-05	0.000421	CcSEcCtD
Sibutramine—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	9.66e-05	0.000421	CcSEcCtD
Sibutramine—SLC6A4—Circadian rythm related genes—HDAC2—chronic obstructive pulmonary disease	9.63e-05	0.00797	CbGpPWpGaD
Sibutramine—Shock—Prednisolone—chronic obstructive pulmonary disease	9.5e-05	0.000415	CcSEcCtD
Sibutramine—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	9.43e-05	0.000411	CcSEcCtD
Sibutramine—SLC6A4—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	9.42e-05	0.0078	CbGpPWpGaD
Sibutramine—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	9.34e-05	0.000407	CcSEcCtD
Sibutramine—Eye disorder—Prednisone—chronic obstructive pulmonary disease	9.23e-05	0.000403	CcSEcCtD
Sibutramine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	9.2e-05	0.00762	CbGpPWpGaD
Sibutramine—SLC6A3—Monoamine Transport—TNF—chronic obstructive pulmonary disease	9.2e-05	0.00762	CbGpPWpGaD
Sibutramine—Angiopathy—Prednisone—chronic obstructive pulmonary disease	8.96e-05	0.000391	CcSEcCtD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	8.93e-05	0.0074	CbGpPWpGaD
Sibutramine—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	8.92e-05	0.000389	CcSEcCtD
Sibutramine—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	8.83e-05	0.000385	CcSEcCtD
Sibutramine—SLC6A2—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	8.82e-05	0.0073	CbGpPWpGaD
Sibutramine—Insomnia—Prednisolone—chronic obstructive pulmonary disease	8.74e-05	0.000381	CcSEcCtD
Sibutramine—Alopecia—Prednisone—chronic obstructive pulmonary disease	8.73e-05	0.000381	CcSEcCtD
Sibutramine—SLC6A2—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	8.69e-05	0.0072	CbGpPWpGaD
Sibutramine—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	8.67e-05	0.000378	CcSEcCtD
Sibutramine—Malnutrition—Prednisone—chronic obstructive pulmonary disease	8.6e-05	0.000375	CcSEcCtD
Sibutramine—SLC6A3—Neuronal System—CHRNA3—chronic obstructive pulmonary disease	8.3e-05	0.00687	CbGpPWpGaD
Sibutramine—Pain—Prednisolone—chronic obstructive pulmonary disease	8.26e-05	0.00036	CcSEcCtD
Sibutramine—Vision blurred—Prednisone—chronic obstructive pulmonary disease	8.11e-05	0.000354	CcSEcCtD
Sibutramine—SLC6A2—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	8.1e-05	0.00671	CbGpPWpGaD
Sibutramine—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	7.98e-05	0.000348	CcSEcCtD
Sibutramine—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	7.96e-05	0.000347	CcSEcCtD
Sibutramine—Anaemia—Prednisone—chronic obstructive pulmonary disease	7.95e-05	0.000347	CcSEcCtD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	7.91e-05	0.00655	CbGpPWpGaD
Sibutramine—Agitation—Prednisone—chronic obstructive pulmonary disease	7.9e-05	0.000345	CcSEcCtD
Sibutramine—Angioedema—Prednisone—chronic obstructive pulmonary disease	7.86e-05	0.000343	CcSEcCtD
Sibutramine—SLC6A3—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	7.81e-05	0.00647	CbGpPWpGaD
Sibutramine—Malaise—Prednisone—chronic obstructive pulmonary disease	7.76e-05	0.000338	CcSEcCtD
Sibutramine—Vertigo—Prednisone—chronic obstructive pulmonary disease	7.73e-05	0.000337	CcSEcCtD
Sibutramine—Syncope—Prednisone—chronic obstructive pulmonary disease	7.71e-05	0.000336	CcSEcCtD
Sibutramine—SLC6A3—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	7.7e-05	0.00638	CbGpPWpGaD
Sibutramine—Urticaria—Prednisolone—chronic obstructive pulmonary disease	7.67e-05	0.000335	CcSEcCtD
Sibutramine—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	7.56e-05	0.00033	CcSEcCtD
Sibutramine—Convulsion—Prednisone—chronic obstructive pulmonary disease	7.45e-05	0.000325	CcSEcCtD
Sibutramine—Hypertension—Prednisone—chronic obstructive pulmonary disease	7.43e-05	0.000324	CcSEcCtD
Sibutramine—Arthralgia—Prednisone—chronic obstructive pulmonary disease	7.32e-05	0.000319	CcSEcCtD
Sibutramine—Myalgia—Prednisone—chronic obstructive pulmonary disease	7.32e-05	0.000319	CcSEcCtD
Sibutramine—Anxiety—Prednisone—chronic obstructive pulmonary disease	7.3e-05	0.000318	CcSEcCtD
Sibutramine—Discomfort—Prednisone—chronic obstructive pulmonary disease	7.23e-05	0.000316	CcSEcCtD
Sibutramine—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	7.22e-05	0.00598	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	7.18e-05	0.00594	CbGpPWpGaD
Sibutramine—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	7.12e-05	0.00031	CcSEcCtD
Sibutramine—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	7.02e-05	0.000306	CcSEcCtD
Sibutramine—Oedema—Prednisone—chronic obstructive pulmonary disease	7.02e-05	0.000306	CcSEcCtD
Sibutramine—Infection—Prednisone—chronic obstructive pulmonary disease	6.97e-05	0.000304	CcSEcCtD
Sibutramine—Shock—Prednisone—chronic obstructive pulmonary disease	6.91e-05	0.000301	CcSEcCtD
Sibutramine—Tachycardia—Prednisone—chronic obstructive pulmonary disease	6.85e-05	0.000299	CcSEcCtD
Sibutramine—Skin disorder—Prednisone—chronic obstructive pulmonary disease	6.82e-05	0.000297	CcSEcCtD
Sibutramine—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	6.79e-05	0.000296	CcSEcCtD
Sibutramine—Anorexia—Prednisone—chronic obstructive pulmonary disease	6.69e-05	0.000292	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	6.4e-05	0.000279	CcSEcCtD
Sibutramine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	6.39e-05	0.000279	CcSEcCtD
Sibutramine—Insomnia—Prednisone—chronic obstructive pulmonary disease	6.35e-05	0.000277	CcSEcCtD
Sibutramine—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	6.3e-05	0.000275	CcSEcCtD
Sibutramine—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	6.18e-05	0.00027	CcSEcCtD
Sibutramine—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	6.1e-05	0.000266	CcSEcCtD
Sibutramine—Rash—Prednisolone—chronic obstructive pulmonary disease	6.09e-05	0.000266	CcSEcCtD
Sibutramine—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	6.09e-05	0.000265	CcSEcCtD
Sibutramine—Headache—Prednisolone—chronic obstructive pulmonary disease	6.05e-05	0.000264	CcSEcCtD
Sibutramine—Constipation—Prednisone—chronic obstructive pulmonary disease	6e-05	0.000262	CcSEcCtD
Sibutramine—SLC6A4—Circadian rythm related genes—LEP—chronic obstructive pulmonary disease	6e-05	0.00497	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	5.97e-05	0.00495	CbGpPWpGaD
Sibutramine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	5.84e-05	0.00484	CbGpPWpGaD
Sibutramine—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	5.78e-05	0.000252	CcSEcCtD
Sibutramine—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	5.76e-05	0.00477	CbGpPWpGaD
Sibutramine—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	5.74e-05	0.00025	CcSEcCtD
Sibutramine—Nausea—Prednisolone—chronic obstructive pulmonary disease	5.74e-05	0.00025	CcSEcCtD
Sibutramine—SLC6A4—Circadian rythm related genes—NOS2—chronic obstructive pulmonary disease	5.59e-05	0.00463	CbGpPWpGaD
Sibutramine—Urticaria—Prednisone—chronic obstructive pulmonary disease	5.58e-05	0.000243	CcSEcCtD
Sibutramine—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	5.55e-05	0.000242	CcSEcCtD
Sibutramine—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	5.55e-05	0.000242	CcSEcCtD
Sibutramine—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	5.25e-05	0.00435	CbGpPWpGaD
Sibutramine—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	5.17e-05	0.000226	CcSEcCtD
Sibutramine—Asthenia—Prednisone—chronic obstructive pulmonary disease	5.04e-05	0.00022	CcSEcCtD
Sibutramine—Pruritus—Prednisone—chronic obstructive pulmonary disease	4.97e-05	0.000217	CcSEcCtD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	4.88e-05	0.00405	CbGpPWpGaD
Sibutramine—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	4.8e-05	0.000209	CcSEcCtD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	4.73e-05	0.00392	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—SERPINE1—chronic obstructive pulmonary disease	4.71e-05	0.0039	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	4.69e-05	0.00388	CbGpPWpGaD
Sibutramine—Dizziness—Prednisone—chronic obstructive pulmonary disease	4.64e-05	0.000202	CcSEcCtD
Sibutramine—Vomiting—Prednisone—chronic obstructive pulmonary disease	4.46e-05	0.000195	CcSEcCtD
Sibutramine—Rash—Prednisone—chronic obstructive pulmonary disease	4.43e-05	0.000193	CcSEcCtD
Sibutramine—Dermatitis—Prednisone—chronic obstructive pulmonary disease	4.42e-05	0.000193	CcSEcCtD
Sibutramine—Headache—Prednisone—chronic obstructive pulmonary disease	4.4e-05	0.000192	CcSEcCtD
Sibutramine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	4.24e-05	0.00351	CbGpPWpGaD
Sibutramine—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	4.19e-05	0.00347	CbGpPWpGaD
Sibutramine—Nausea—Prednisone—chronic obstructive pulmonary disease	4.17e-05	0.000182	CcSEcCtD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	3.97e-05	0.00329	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	3.84e-05	0.00318	CbGpPWpGaD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	3.44e-05	0.00285	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	3.4e-05	0.00282	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	3.3e-05	0.00273	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	3.29e-05	0.00272	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	3.03e-05	0.00251	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	2.99e-05	0.00248	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	2.92e-05	0.00242	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	2.91e-05	0.00241	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	2.78e-05	0.00231	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	2.74e-05	0.00227	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	2.52e-05	0.00208	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	2.48e-05	0.00205	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	2.47e-05	0.00204	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	2.45e-05	0.00203	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	2.24e-05	0.00186	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	2.1e-05	0.00174	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	2.07e-05	0.00171	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	1.93e-05	0.0016	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	1.9e-05	0.00157	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	1.83e-05	0.00151	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	1.8e-05	0.00149	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.67e-05	0.00138	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.48e-05	0.00123	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	1.47e-05	0.00122	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	9.74e-06	0.000806	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	9.47e-06	0.000785	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	8.81e-06	0.000729	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.18e-06	0.000429	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	5.12e-06	0.000424	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	4.67e-06	0.000387	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.3e-06	0.000356	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.59e-06	0.000297	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.54e-06	0.000293	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.3e-06	0.000273	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.13e-06	0.000259	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	2.12e-06	0.000176	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	2.03e-06	0.000168	CbGpPWpGaD
